Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Mamoru Shiga, Naoaki Ban, Kazunobu Kuwabara, Hideharu Hata, Daishuke Ohira, Toshinori Nasu, Mashahiro Hiroshe, Rieko Kondou, Takahiko Horiguchi

Research output: Contribution to journalArticlepeer-review

Abstract

Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

Original languageEnglish
Pages (from-to)1254-1260
Number of pages7
JournalJapanese Journal of Chest Diseases
Volume71
Issue number12
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)'. Together they form a unique fingerprint.

Cite this